secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001104659-25-099029
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a
--------------------------------------------------------------------------------

- 16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
- Median treatment duration of 4 months (range 2–12); three patients remain on trial.
- 44% (7/16) achieved stable disease lasting ≥4 months per RECIST; one thyroid cancer patient had undetectable thyroglobulin.
- Recommended Phase 2 dose established; company plans to initiate Phase 2a efficacy trial.
- PK profile shows predictable exposure; pharmacodynamic effects consistent with preclinical models and prior Phase 0.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925099029/0001104659-25-099029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925099029/tm2528668d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer